A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)

This is a Phase Ib in adult patients with relapsed or refractory EBV-positive DLBCL using daily oral dosing of VK-2019 in three dose escalation cohorts: 600 mg/day, 1200 mg/day, 1800 mg/day for 28 days (cycle), until progression or toxicity.

Trial Details

NCT ID
NCT06789159
Phase
PHASE1
Sponsor
Pierluigi Porcu
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • VK-2019
Locations (sample)
  • Lexington, Kentucky, United States|37.98869,-84.47772

Key Eligibility Criteria

  • Informed consent obtained prior to any protocol mandated assessment.
  • Age ≥ 18 years.
  • Patient must have relapsed or refractory EBV-positive DLBCL after a minimum of 2 prior regimens of systemic therapy.
  • Patient must have exhausted all available standard of care treatment options that could potentially provide clinical benefit.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →